The Role of Neutrophil Gelatinase-Associated Lipocalin and N-Terminal Pro B-Type Natriuretic Peptide in the Prediction of Heart Failure in Patients with Acute Coronary Syndrome
DOI:
https://doi.org/10.3889/oamjms.2022.10897Keywords:
Acute coronary syndrome, Heart failure, Prognostic, NT-proBNP, NGALAbstract
BACKGROUND: Heart failure, where the heart cannot pump blood effectively, significantly affects patient quality of life and impacts national health-care services. Acute coronary syndrome is a common underlying cause of acute heart failure. Neutrophil gelatinase-binding lipocalin (NGAL) and N-terminal pro B-type natriuretic peptide (NT-proBNP) are biomarkers released during myocardial injury. Thus, the measured levels of these chemicals may be associated with heart failure events in patients with acute coronary syndrome.
AIM: The present study determined the serum levels and measured increases in NGAL and NT-proBNP, as well as recorded heart failure events in patients with acute coronary syndrome in Vietnam.
METHODS: A descriptive cross-sectional method was used to recruit 58 patients with acute coronary syndrome and assess the degree to which the two markers could predict ejection fraction (EF).
RESULTS: The median values of NGAL and NT-proBNP concentrations in the group with EF ≥40% (7.14 ng/mL and 952.00 pg/mL) were significantly lower than those with EF <40% (166.10 ng/mL and 27,498.00 pg/mL). NGAL was used to predict heart failure events at a threshold of 94.86 ng/mL with a sensitivity of 83.3%, a specificity of 90.4%, and an area under the curve (AUC) of 0.83. Similarly, NT-proBNP predicted heart failure events at a threshold of 8660.5 pg/mL with a sensitivity of 83.3%, a specificity of 84.6%, and an AUC of 0.79.
CONCLUSIONS: Serum NGAL and NT-proBNP levels can be used as reliable biomarkers for predicting heart failure events in patients with acute coronary syndrome.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Aleksova A, Sinagra G, Beltrami AP, Pierri A, Ferro F, Gagno G, et al. Biomarkers in the management of acute heart failure: State of the art and role in COVID-19 era. ESC Heart Fail. 2021;8(6):4465-83. https://doi.org/10.1002/ehf2.13595 PMid:34609075
Lam CS, Li YH, Bayes-Genis A, Ariyachaipanich A, Huan DQ, Sato N, et al. The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. J Chin Med Assoc. 2019;82(6):447-51. https://doi.org/10.1097/JCMA.0000000000000102 PMid:31180944
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. https://doi.org/10.1056/NEJMoa020265 PMid:12409541
Berezin A. Up-to-date clinical approaches of biomarkers’ use in heart failure. Biomed Res Ther. 2017;4(6):1344-73. https://doi.org/10.15419/bmrat.v4i06.178
Palazzuoli A, Beltrami M, Pellegrini M, Nuti R. Natriuretic peptides and NGAL in heart failure: Does a link exist? Clin Chim Acta. 2012;413(23-24):1832-8. https://doi.org/10.1016/j.cca.2012.07.010 PMid:22820397
Song X, Cai D, Zhang B. Clinical values of serum NGAL combined with NT-proBNP in the early prognosis of Type 1 cardiorenal syndrome. Am J Transl Res. 2021;13(4):3363-8. eCollection 2021. PMid:34017511
Bauvois B, Susin SA. Revisiting neutrophil gelatinase-associated lipocalin (NGAL) in cancer: saint or sinner? Cancers (Basel). 2018;10(9):336. https://doi.org/10.3390/cancers10090336 PMid:30231474
Wettersten N, Maisel A. Role of cardiac troponin levels in acute heart failure. Card Fail Rev. 2015;1(2):102-6. https://doi.org/10.15420/cfr.2015.1.2.102 PMid:28785441
Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019;20(8):1820. https://doi.org/10.3390/IJMS20081820 PMid:31013779
Helanova K, Littnerova S, Kubena P, Ganovska E, Pavlusova M, Kubkova L, et al. Prognostic impact of neutrophil gelatinase-associated lipocalin and B-type natriuretic in patients with ST-elevation myocardial infarction treated by primary PCI: A prospective observational cohort study. BMJ Open. 2015;5(10):e006872. https://doi.org/10.1136/bmjopen-2014-006872 PMid:26438132
Liu H, Wan X, Shi Y, Huang F, Shu H, Huang R, et al. Neutrophil gelatinase-associated lipocalin contributes to increased risk of cardiovascular death after acute coronary syndrome. Int J Gen Med. 2021;14:4887-95. https://doi.org/10.2147/IJGM.S328022 PMid:34475780
Thai HP, Bui BH, Anh TH, Huynh Van M. Value of plasma NGAL and creatinine on first day of admission in the diagnosis of cardiorenal syndrome Type 1. Cardiol Res Pract. 2020;2020:2789410. https://doi.org/10.1155/2020/2789410 PMid:33083054
Thanh BD, Son NH, Pho DC, Bac ND, Nga VT, Dung QA, et al. The role of serial NT-ProBNP level in prognosis and follow-up treatment of acute heart failure after coronary artery bypass graft surgery. Open Access Maced J Med Sci. 2019;7(24):4411-5. https://doi.org/10.3889/oamjms.2019.872 PMid:32215104
Son TK, Toan NH, Thang N, Tuong HL, Tien HA, Thuy NH, et al. Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension. Cardiovasc Diabetol. 2022;21(1):75. https://doi.org/10.1186/s12933-022-01509-5 PMid:35568879
Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280-7. https://doi.org/10.1001/jamacardio.2018.0022 PMid:29490333
Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(12):1246-58. https://doi.org/10.4239/wjd.v6.i13.1246 PMid:26468341
Gharishvandi F, Kazerouni F, Ghanei E, Rahimipour A, Nasiri M. Comparative assessment of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C as early biomarkers for early detection of renal failure in patients with hypertension. Iran Biomed J. 2015;19(2):76-81. https://doi.org/10.6091/ibj.1380.2015 PMid:25864811
Eirin A, Gloviczki ML, Tang H, Rule AD, Wollard JR, Lerman A, et al. Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin. Nephrol Dial Transplant. 2012;27(11):4153-61. https://doi.org/10.1093/ndt/gfs370 PMid:22923545
Van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, Hillege HL, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail. 2014;7(1):35-42. https://doi.org/10.1161/circheartfailure.113.000242 PMid:24347663
Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL evaluation along with B-type NaTriuretic peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13(8):846-51. https://doi.org/10.1093/eurjhf/hfr087 PMid:21791540
Lábr K, Špinar J, Pařenica J, Špinarová L, Málek F, Špinarová M, et al. Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin. Kidney Blood Press Res. 2018;43:1865-77. https://doi.org/10.1159/000495819
Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30:1229-36. https://doi.org/10.1093/eurheartj/ehp088 PMid:19329498
Alvelos M, Lourenço P, Dias C, Amorim M, Rema J, Leite AB, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2013;165(1):51-5. https://doi.org/10.1016/j.ijcard.2011.07.080 PMid:21872946
Kirbiš S, Gorenjak M, Sinkovič A. The role of urine neutrophil gelatinase--associated lipocalin (NGAL) in acute heart failure in patients with ST--elevation myocardial infarction. BMC Cardiovasc Disord. 2015;15:49. https://doi.org/10.1186/S12872-015-0054-9
Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-54. https://doi.org/10.1016/j.amjcard.2004.12.032 PMid:15820160
Karetnikova V, Osokina A, Gruzdeva O, Uchasova E, Zykov M, Kalaeva V, et al. Serum neutrophil gelatinase-associated lipocalin the estimation of hospital prognosis in patients with ST-elevated myocardial infarction. PLoS One. 2017;12(7):e0180816. https://doi.org/10.1371/journal.pone.0180816 PMid:28742104
Taskapan H, Taskapan MC, Orman I, Ulutas O, Yigit A, OzyalinF, et al. NGAL and NT-proBNP levels in diabetic patients with macroproteinuria. Ren Fail. 2013;35(9):1273-7 http://doi.org/10.3109/0886022X.2013.824336 PMid:23964619
Lindberg S, Jensen JS, Mogelvang R, Pedersen SH, Galatius S, Flyvbjerg A, et al. Plasma neutrophil gelatinase-associated lipocalinin in the general population: Association with inflammation and prognosis. Arterioscler Thromb Vasc Biol. 2014;34(9):2135-42. https://doi.org/10.1161/ATVBAHA.114.303950 PMid:24969771
Schellings DA, Adiyaman A, Dambrink JH, Gosselink AT, Kedhi E, Roolvink V, et al. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: A comparison with the grace and timi risk scores. Vasc Health Risk Manag. 2016;12:471-6. https://doi.org/10.2147/VHRM.S117204 PMid:27920547
Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: Results from CORONA*. J Intern Med. 2012;271(5):436-43. https://doi.org/10.1111/j.1365-2796.2011.02503.x PMid:22211640
Anguita M, Montes P, Jordán A, Casares G, Gómez I, Recio J, et al. Utility of NT-proBNP for diagnosing heart failure in a heterogeneous population of patients with dyspnea. Spanish multicenter study. Rev Esp Cardiol. 2006;59(5):465-72. PMid:16750144
Tschöpe C, Kašner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26(21):2277-84. https://doi.org/10.1093/eurheartj/ehi406 PMid:16014646
Nakada Y, Kawakami R, Matsui M, Ueda T, Nakano T, Takitsume A, et al. Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J Am Heart Assoc. 2017;6(5):e004582. https://doi.org/10.1161/jaha.116.004582 PMid:28522674
Yoshikawa K, Iwasa M, Eguchi A, Kojima S, Yoshizawa N, Tempaku M, et al. Neutrophil gelatinase-associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases. Hepatol Commun. 2017;1(9):946-56. https://doi.org/10.1002/hep4.1109 PMid:29404502
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 An Viet Tran, Nguyet To Tran, Khue Duy Nguyen, An Tuan Huynh, Diem Thi Nguyen, Khuong Duy Nguyen, Thang Nguyen, Van De Tran, Rebecca Susan Dewey (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
